((自动化翻译由路透提供，请见免责声明 )) (第2-4段增加了研究细节和下一步措施)
路透1月6日 - Denali Therapeutics 周一表示，其实验性药物未能达到一项涉及肌萎缩性脊髓侧索硬化症（amyotrophic lateral sclerosis(ALS)，一种致命的神经退行性疾病）患者的中后期试验的主要目标。
消息公布后，这家药物开发商的股票在延时交易中下跌了 6.6%。
该研究的主要目标是通过特定的量表测量，将DNL343与安慰剂进行比较，证明随着时间的推移，疾病的严重程度会发生变化，存活率会提高。
"该研究的主要研究者 Merit Cudkowicz 说："我们将继续致力于全面了解 DNL343 对 ALS 的影响，并将在确定下一步之前进一步评估数据。
该公司医学主管 Carole Ho 表示，将在 2025 年晚些时候对研究结果进行更全面的分析。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.